AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been assigned a $4.00 target price by Maxim Group in a report released on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective suggests a potential upside of 131.21% from the stock’s current price.

AEZS has been the topic of a number of other research reports. Zacks Investment Research lowered AEterna Zentaris from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. HC Wainwright lowered their price objective on AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th.

AEterna Zentaris (NASDAQ AEZS) traded up 25.6474% during mid-day trading on Friday, reaching $2.1737. The company had a trading volume of 3,703,892 shares. The stock’s market capitalization is $31.16 million. AEterna Zentaris has a 52 week low of $0.78 and a 52 week high of $5.59. The stock has a 50 day moving average of $1.53 and a 200 day moving average of $2.09.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.05. The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.22 million. AEterna Zentaris had a negative return on equity of 425.52% and a negative net margin of 2,732.69%. AEterna Zentaris’s quarterly revenue was up 153.1% compared to the same quarter last year. Analysts anticipate that AEterna Zentaris will post ($1.36) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/aeterna-zentaris-inc-nasdaqaezs-pt-set-at-4-00-by-maxim-group/1472756.html.

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.